Banner with Dr. Kamlesh Yadav headshot
Research from EnMed professor Dr. Kamlesh Yadav was recently shared at the world’s largest human genetics and genomics meeting.

Three abstracts co-authored by Dr. Kamlesh Yadav, instructional associate professor at the Intercollegiate School of Engineering Medicine, were recently featured at the 2021 annual meeting for the American Society of Human Genetics (ASHG). The ASHG’s annual meeting is the largest human genetics and genomics meeting and exposition in the world.

Held Oct. 18-22, the meeting provided a forum for the presentation and discussion of cutting-edge science in all areas of human genetics.

Yadav was a part of research teams that presented the following three abstracts at the meeting:

  1. Timer CAR-T (TCAR-T): A paradigm shift in CAR-T cell therapy

While CAR-T cell therapy has shown immense potential in cancer treatment, certain side effects present unique challenges. Researchers propose that developing genetically modified timer CAR-T (TCAR-T) cells that can act temporally through external modulations, including their complete elimination, will reduce long-term side effects upon successful tumor remission. 

  1. Cancer informatics survey of different grades and subtypes of glioma 

Gliomas are one of the leading causes of death in middle age population. This study explores the similarities and differences between different grades and subtypes of gliomas. The molecular trajectory that evolves around the key glioma-related genes was determined, along with drug repositioning candidates, to enhance future treatment strategies.

  1. A translational bioinformatics investigation of the human gut microbiome and hypertensive diseases 

Dysbiosis is a condition when the gut bacteria become imbalanced. This study explores the involvement of various gut microbes in hypertensive diseases through the identification of metabolic pathways shared between them. Furthermore, the researchers also describe a pathway-based drug repositioning approach to identify therapeutic vulnerability to target some of the prominent pathways.